ProteinQure Inc.
25.3.2024 05:03:30 CET | ACCESS Newswire | Press release
TORONTO, ON / ACCESSWIRE / March 25, 2024 / ProteinQure, the leading startup in the computational design of peptide drugs, announces a significant breakthrough in the fight against triple-negative breast cancer (TNBC). The novel Peptide Drug Conjugate (PDC) designed by ProteinQure demonstrated exceptional efficacy in a comprehensive suite of Patient-Derived Xenograft (PDX) models. The experiments were conducted in the lab of Dr. David Cescon at the Princess Margaret Cancer Centre/University Health Network, one of the world's top five cancer research centres.
Developed through ProteinQure's cutting-edge computational platform, the innovative SORT1 targeting PDC is a novel peptide attached to a highly potent chemotherapeutic agent. The drug candidate was tested across a broad range of breast cancer models. The results demonstrated remarkable antitumor efficacy, including cancers resistant to standard chemotherapies and antibody-drug conjugates.
"Working with the David Cescon Lab at UHN has been instrumental in validating our novel PDC's efficacy against one of the most challenging forms of breast cancer. Based on these results, we are moving our lead program forward into IND-Enabling studies and our first clinical trial," said Lucas Siow, CEO of ProteinQure. "These findings not only highlight the power of our computational drug design platform but also represent significant validation in our quest to develop tissue-specific peptides for targeted drug delivery."
ProteinQure's collaborators will present the data at the upcoming American Association for Cancer Research (AACR) conference in San Diego. The AACR conference, renowned for showcasing the latest innovations in cancer research, provides the perfect stage to share these findings with the global cancer research community.
"We are excited to present this data at AACR and help develop new therapeutic options for breast cancer, especially with promising Canadian startups," stated Dr. David Cescon, head of the lab at UHN. "The success of this unique PDC in diverse PDX models is a testament to the potential of combining advanced computational techniques, precision oncology, and our labs' robust preclinical platform".
Funding for parts of this work included contributions from IRAP-Canada and the INOVAIT program based out of Sunnybrook Hospital.
Poster Presentation Details:
Title: In-vivo efficacy of a novel peptide-conjugated drug in patient-derived xenograft models of breast cancer
Session Title: New Targets
Date and Time: Tuesday, April 9, at 1:30 p.m. PT/4:30 p.m. ET
Abstract Number: 5911
Speaker: Mitchell Elliott, UHN Princess Margaret Cancer Centre
About ProteinQure
ProteinQure is a pioneering startup specializing in the computational design of peptide drugs utilizing state-of-the-art artificial intelligence and molecular simulation technologies. With a focus on precision medicine, ProteinQure is dedicated to transforming the landscape of drug development and ushering in a new era of targeted effective treatments.
About the David Cescon Lab at UHN
The David Cescon Lab at the University Health Network is a leader in breast cancer research, focusing on the mechanisms of cancer progression and resistance to therapy. Through cutting-edge pre-clinical and clinical research and collaborations, the lab develops novel therapeutic strategies aimed at improving outcomes for cancer patients worldwide.
For further information, please contact:
Lucas Siow - CEO of ProteinQure - press@proteinqure.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
SOURCE: ProteinQure Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GA-ASI Completes MQ-9B 'Flight Into Known Icing' Flight Tests20.4.2026 15:00:00 CEST | Press release
Global RPA Leader Is Certifying MQ-9B for FIKI SAN DIEGO, CA / ACCESS Newswire / April 20, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) has conducted a series of flight tests aimed at certifying the MQ-9B Remotely Piloted Aircraft (RPA) for Flight Into Known Icing (FIKI). The flight tests began last year, and all planned testing was successfully completed in early April from GA-ASI's Flight Test & Training Center (FTTC) near Grand Forks, North Dakota, using a company-owned MQ-9B. The FIKI flights build on earlier successful flight tests to evaluate flight characteristics with simulated ice shapes adhered to the aircraft as well as the aircraft's successful Cold Weather Validation and flights in the Arctic. FIKI certification will expand MQ-9B's abilities to provide all-weather surveillance capabilities for the many nations that have purchased the system for their military and civil support missions. The tests were flown using GA-ASI Internal Research and Development fundi
GA-ASI Completes MQ-9B 'Flight Into Known Icing' Flight Tests20.4.2026 15:00:00 CEST | Press release
Global RPA Leader Is Certifying MQ-9B for FIKI SAN DIEGO, CA / ACCESS Newswire / April 20, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) has conducted a series of flight tests aimed at certifying the MQ-9B Remotely Piloted Aircraft (RPA) for Flight Into Known Icing (FIKI). The flight tests began last year, and all planned testing was successfully completed in early April from GA-ASI's Flight Test & Training Center (FTTC) near Grand Forks, North Dakota, using a company-owned MQ-9B. The FIKI flights build on earlier successful flight tests to evaluate flight characteristics with simulated ice shapes adhered to the aircraft as well as the aircraft's successful Cold Weather Validation and flights in the Arctic. FIKI certification will expand MQ-9B's abilities to provide all-weather surveillance capabilities for the many nations that have purchased the system for their military and civil support missions. The tests were flown using GA-ASI Internal Research and Development fundi
Loar Holdings Inc. Announces Date and Time for First Quarter 2026 Earnings and Conference Call17.4.2026 15:15:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / April 17, 2026 / Loar Holdings Inc. (NYSE:LOAR), will report Q1 2026 earnings before the market opens on Thursday, May 7, 2026. A conference call will follow at 10:30a.m., Eastern Time. To participate in the call telephonically please dial +1 877-407-0670/+1 215-268-9902. International participants can find a list of toll-free numbers here. A live audio webcast will also be available at the following link as well as through the Investor section of Loar Holdings website; https://ir.loargroup.com The webcast will be archived and available for replay later in the day. About Loar Holdings Inc. Loar Holdings Inc. is a diversified manufacturer and supplier of niche aerospace and defense components that are essential for today's aircraft and aerospace and defense systems. Loar has established relationships across leading aerospace and defense original equipment manufacturers and Tier Ones worldwide. Contact: Ian McKillop Loar Holdings Inc. Investor Relatio
Loar Holdings Inc. Announces Date and Time for First Quarter 2026 Earnings and Conference Call17.4.2026 15:15:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / April 17, 2026 / Loar Holdings Inc. (NYSE:LOAR), will report Q1 2026 earnings before the market opens on Thursday, May 7, 2026. A conference call will follow at 10:30a.m., Eastern Time. To participate in the call telephonically please dial +1 877-407-0670/+1 215-268-9902. International participants can find a list of toll-free numbers here. A live audio webcast will also be available at the following link as well as through the Investor section of Loar Holdings website; https://ir.loargroup.com The webcast will be archived and available for replay later in the day. About Loar Holdings Inc. Loar Holdings Inc. is a diversified manufacturer and supplier of niche aerospace and defense components that are essential for today's aircraft and aerospace and defense systems. Loar has established relationships across leading aerospace and defense original equipment manufacturers and Tier Ones worldwide. Contact: Ian McKillop Loar Holdings Inc. Investor Relatio
Karbon-X Launches SkyXero, a New App for Flight Emissions Tracking as Travelers Seek Trusted Climate Solutions17.4.2026 15:00:00 CEST | Press release
New mobile app enables real-time flight emissions tracking and access to verified climate projects worldwide, launching during Earth Month. CALGARY, AB / ACCESS Newswire / April 17, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions provider operating across compliance and voluntary carbon markets, today announced the launch of SkyXero, a new mobile application that enables travelers to measure and balance the emissions of their flights in a few taps. Launching during Earth Month, a period of heightened global focus on environmental impact, SkyXero is now available globally and is designed to meet the growing demand from travelers seeking practical, trusted ways to incorporate climate considerations into their travel decisions. SkyXero allows users to enter flight details, instantly calculate associated emissions, and contribute to a curated portfolio of high-integrity, third-party verified climate projects, including those certi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom